BG Medicine, Inc.

BGMD

US08861T2069

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 10:36:41 2023-12-06 am EST			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-.--%

2016	BG Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2015	CI
2016	BG Medicine Announces Board Changes	CI

BG Medicine, Inc. Terminates the Employment of Stephen R. Miller as the Chief Commercial Officer

September 12, 2012 at 05:04 pm EDT

The employment of Stephen R. Miller, the Chief Commercial Officer of BG Medicine, Inc. was terminated effective as of September 6, 2012. Mr. Miller will receive the severance pay to which he is entitled under his previously filed employment agreement. He has also agreed to consult for the Company on an interim basis following his termination.

Latest news about BG Medicine, Inc.

BG Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2015	16-03-31	CI
BG Medicine Announces Board Changes	16-02-04	CI
BG Medicine Withdraws 510(K) Premarket Notification for Proposed Additional Indication for the Bgm Galectin-3® Test	15-12-23	CI
BG Medicine, Inc. Amends License and Distribution Agreement for Galectin-3 with Abbott Laboratories	15-11-30	CI
BG Medicine, Inc. Announces Board Changes	15-11-20	CI
Transcript : BG Medicine, Inc. - Special Call	15-11-17
BG Medicine, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	15-11-17	CI
Certain Options of BG Medicine, Inc. are subject to a Lock-Up Agreement Ending on 11-NOV-2015.	15-11-10	CI
Certain Warrants of BG Medicine, Inc. are subject to a Lock-Up Agreement Ending on 11-NOV-2015.	15-11-10	CI
Certain shares of BG Medicine, Inc.'s Common Stock are subject to a Lock-Up Agreement Ending on 11-NOV-2015.	15-11-10	CI
Timothy Harris Resigns to Board of Directors and Audit Committee of BG Medicine, Inc	15-09-25	CI
BG Medicine, Inc.(OTCPK:BGMD) dropped from MSCI Acwi + Frontier Markets(acwi Fm) All Cap Index	15-09-17	CI
BG Medicine, Inc.(OTCPK:BGMD) dropped from S&P TMI Index	15-09-17	CI
BG Medicine, Inc.(OTCPK:BGMD) dropped from CRSP US Total Market Index	15-09-16	CI
BG Medicine, Inc.(NasdaqCM:BGMD) dropped from NASDAQ Composite Index	15-09-15	CI
Transcript : BG Medicine, Inc., Q2 2015 Earnings Call, Aug 19, 2015	15-08-19
BG Medicine, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015	15-08-14	CI
BG Medicine, Inc. Announces Payoff of Secured Term Loan	15-07-15	CI
BG Medicine, Inc. announced that it has received $2.5 million in funding from Flagship Ventures.	15-07-13	CI
BG Medicine, Inc. Announces First Automated Test for Galectin-3 Now Available in U.S	15-07-06	CI
BGMD Seeks Acquisitions	15-05-19	CI
Transcript : BG Medicine, Inc., Q1 2015 Earnings Call, May 14, 2015	15-05-14
BG Medicine, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Financial Guidance for 2015	15-05-14	CI
BG Medicine, Inc. Announces Board Changes	15-05-12	CI
BG Medicine, Inc. announced that it expects to receive $2.5 million in funding from Flagship Ventures.	15-05-11	CI

Chart BG Medicine, Inc.

Duration

Period

More charts

Company Profile

BG Medicine, Inc. (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company's BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners' automated platforms. The Company's CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.

Sector

Pharmaceuticals

More about the company